最近，一种新的牙源性肿瘤被描述为腺样基底细胞化物质牙母瘤（AdAM）。本综述的目的是确定AdAM的临床和影像特征，并描述其主要的组织病理学发现。系统综述包括在颌骨中确诊为AdAM，且具备足够临床、影像和组织病理学数据以确诊的已发表病例。采用以下组织病理学诊断标准：存在类似牙母瘤样成分、管状结构、螺旋状细胞凝聚和筛状结构。 选择了15篇文章，对应30例AdAM病例。大多数病例影响男性（63.3％），略有偏好于下颌骨（16:14），颌骨后部是最常受累的部位。平均诊断年龄为40.8岁。临床上，肿块通常呈现为肿胀（53.3％），放射学上呈现为明确定义的放射透亮区（33.4％）。手术切除（40％）是最常采用的治疗方法，复发发生在30％的病例中。镜检显示大多数AdAM病例中存在筛状区域（93.3％）；管状结构和螺旋状细胞凝聚在所有病例中均可见。 报道的病例数量少、存在错误诊断和采用初始保守管理使得确定AdAM是否具有比传统牙母瘤更高的复发风险或更具侵袭性生物行为变得困难。 © 2023. 作者（们），在Spinger Science+Business Media, LLC独家许可，隶属于Springer Nature。

Recently, a new odontogenic tumor has been described, the so-called adenoid ameloblastoma (AdAM). The aim of this review was to determine the clinical and imaging features of AdAM and to describe its main histopathological findings.The systematic review included published cases with a diagnosis of AdAM in the gnathic bones, which had sufficient clinical, imaging, and histopathological data to confirm its diagnosis. The following histopathological diagnostic criteria were adopted: presence of ameloblastoma-like components, duct-like structures, spiral cellular condensations, and a cribriform architecture.Fifteen articles, corresponding to 30 cases of AdAM, were selected. Most cases affected men (63.3%), with a slight preference for the mandible (16:14) and the posterior region of gnathic bones was the most commonly affected site. The mean age at diagnosis was 40.8 years. Clinically, the lesions usually presented as a swelling (53.3%) and, radiographically, as a well-defined radiolucency (33.4%). Surgical resection (40%) was the most frequently adopted treatment and recurrence occurred in 30% of cases. Microscopic examination showed cribriform areas in most AdAM cases (93.3%); duct-like structures and spiral cellular condensations were seen in 100% of the cases.The small number of reported cases, the existence of erroneous diagnoses, and the adoption of initial conservative management make it difficult to determine whether AdAM has a higher risk of recurrence or more aggressive biological behavior than conventional ameloblastomas.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.